SCHEMBL28996709

SCHEMBL28996709

CN1CCN(CCCN(C(=O)OC(C)(C)C)c2cc(Br)ccn2)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 1/20 0.41
▸ OPRM1 P35372 2/20 0.40
▸ HTR1B P28222 1/20 0.40
▸ POLB P06746 1/20 0.38
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ SSTR4 P31391 1/20 0.35
▸ MCHR1 Q99705 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ HTR4 Q13639 1/20 0.35
▸ FGFR1 P11362 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ EGFR P00533 1/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ F2 P00734 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27007095 0.86 OPRM1 (0.47) RAB9AOPRM1HTR1BPOLBMEN1
SCHEMBL30499327 0.84 OPRM1 (0.56) RAB9AOPRM1HTR1BMEN1KMT2A
SCHEMBL26728113 0.78 SSTR4 (0.40) SSTR4ALDH1A1KDM4EF2
SCHEMBL21070417 0.75 CNR2 (0.39) SSTR4ACHEHTR4ALDH1A1KDM4E
SCHEMBL16703527 0.74 SSTR4 (0.41) SSTR4ALDH1A1KDM4EF2
SCHEMBL20049595 0.74 SSTR4 (0.38) SSTR4ALDH1A1KDM4EF2
SCHEMBL24035707 0.72 SYK (0.41) RAB9ASSTR4ALDH1A1KDM4E
SCHEMBL30161746 0.72 SYK (0.41) RAB9ASSTR4ALDH1A1KDM4E
SCHEMBL12678539 0.71 SSTR4 (0.40) SSTR4ALDH1A1KDM4E
SCHEMBL29580743 0.71 SSTR4 (0.40) SSTR4ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-25 — — US disclosed
US-20240018122-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-18 — — US disclosed
EP-4182308-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-05-24 — — EP disclosed
CN-116096719-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2023-05-09 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018122-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS ALK, TGFBR1, ACVR1 RAB9A 3753/4885OPRM1 2019/4885HTR1B 2464/4885
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors ALK, TGFBR1, ACVR1 RAB9A 3753/4885OPRM1 2019/4885HTR1B 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback